Logo image of PRFX

PAINREFORM LTD (PRFX) Stock Price, Forecast & Analysis

USA - NASDAQ:PRFX - IL0011651580 - Common Stock

0.8955 USD
-0.03 (-3.71%)
Last: 11/14/2025, 8:17:45 PM
0.8901 USD
-0.01 (-0.6%)
After Hours: 11/14/2025, 8:17:45 PM

PRFX Key Statistics, Chart & Performance

Key Statistics
Market Cap1.80M
Revenue(TTM)N/A
Net Income(TTM)-14.59M
Shares2.01M
Float1.81M
52 Week High16.63
52 Week Low0.87
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-32.16
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2020-09-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PRFX short term performance overview.The bars show the price performance of PRFX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

PRFX long term performance overview.The bars show the price performance of PRFX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of PRFX is 0.8955 USD. In the past month the price decreased by -27.78%. In the past year, price decreased by -57.82%.

PAINREFORM LTD / PRFX Daily stock chart

PRFX Latest News, Press Relases and Analysis

PRFX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 46.62 970.39B
JNJ JOHNSON & JOHNSON 18.88 471.87B
MRK MERCK & CO. INC. 10.55 232.09B
PFE PFIZER INC 7.83 142.48B
BMY BRISTOL-MYERS SQUIBB CO 7.11 94.95B
ZTS ZOETIS INC 19.06 53.55B
RPRX ROYALTY PHARMA PLC- CL A 9.53 22.84B
VTRS VIATRIS INC 4.6 12.50B
ELAN ELANCO ANIMAL HEALTH INC 21.97 10.48B
CORT CORCEPT THERAPEUTICS INC 85.84 7.96B
AXSM AXSOME THERAPEUTICS INC N/A 6.97B
BLTE BELITE BIO INC - ADR N/A 4.07B

About PRFX

Company Profile

PRFX logo image PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

Company Info

PAINREFORM LTD

65 Yigal Alon St.

TEL AVIV-YAFO 6745442 IL

CEO: Ilan Hadar

Employees: 4

PRFX Company Website

PRFX Investor Relations

Phone: 97237177051

PAINREFORM LTD / PRFX FAQ

What does PAINREFORM LTD do?

PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.


Can you provide the latest stock price for PAINREFORM LTD?

The current stock price of PRFX is 0.8955 USD. The price decreased by -3.71% in the last trading session.


Does PRFX stock pay dividends?

PRFX does not pay a dividend.


How is the ChartMill rating for PAINREFORM LTD?

PRFX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists PRFX stock?

PRFX stock is listed on the Nasdaq exchange.


Can you provide the market cap for PAINREFORM LTD?

PAINREFORM LTD (PRFX) has a market capitalization of 1.80M USD. This makes PRFX a Nano Cap stock.


Who owns PAINREFORM LTD?

You can find the ownership structure of PAINREFORM LTD (PRFX) on the Ownership tab.


PRFX Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PRFX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PRFX. PRFX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PRFX Financial Highlights

Over the last trailing twelve months PRFX reported a non-GAAP Earnings per Share(EPS) of -32.16. The EPS increased by 81.23% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -130.69%
ROE -172.78%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%96.15%
Sales Q2Q%N/A
EPS 1Y (TTM)81.23%
Revenue 1Y (TTM)N/A

PRFX Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y38.91%
Revenue Next YearN/A

PRFX Ownership

Ownership
Inst Owners0.99%
Ins OwnersN/A
Short Float %4.22%
Short Ratio0.02